|
|
|
|
| LEADER |
02694nam a2200421 u 4500 |
| 001 |
EB000943496 |
| 003 |
EBX01000000000000000737086 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
150223 r ||| eng |
| 100 |
1 |
|
|a Gartlehner, Gerald
|
| 245 |
0 |
0 |
|a Drug class review on targeted immune modulators
|h Elektronische Ressource
|b final report
|c Gerald Gartlehner [and 5 others] ; produced by RTI-UNC Evidence-based Practice Center, Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill [and] Oregon Evidence-based Practice Center
|
| 246 |
3 |
1 |
|a Targeted immune modulators
|
| 260 |
|
|
|a Portland, Oregon
|b Oregon Health & Science University
|c [2006], 2006
|
| 300 |
|
|
|a 1 PDF file (148 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Antirheumatic Agents / therapeutic use
|
| 653 |
|
|
|a Drug Evaluation
|
| 653 |
|
|
|a Antibodies, Monoclonal / therapeutic use
|
| 653 |
|
|
|a Immunologic Factors / therapeutic use
|
| 653 |
|
|
|a Immunoglobulin G / therapeutic use
|
| 653 |
|
|
|a Recombinant Fusion Proteins / therapeutic use
|
| 653 |
|
|
|a Immunoconjugates / therapeutic use
|
| 653 |
|
|
|a Interleukin 1 Receptor Antagonist Protein / therapeutic use
|
| 653 |
|
|
|a Treatment Outcome
|
| 710 |
2 |
|
|a Cecil G. Sheps Center for Health Services Research
|
| 710 |
2 |
|
|a RTI International-University of North Carolina Evidence-based Practice Center
|
| 710 |
2 |
|
|a Oregon Health & Science University
|b Evidence-based Practice Center
|
| 710 |
2 |
|
|a Oregon Health & Science University
|
| 710 |
2 |
|
|a Drug Effectiveness Review Project
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Drug class reviews
|
| 500 |
|
|
|a Title from PDF title page. - "January 2007."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK10567
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 856 |
4 |
0 |
|u http://www.donau-uni.ac.at/imperia/md/content/department/evidenzbasierte_medizin/abstracts_publikationen_gerald/drug_class_review_on_targeted_immune_modulators.pdf
|3 Volltext
|n Free Electronic Resource
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Targeted immune modulators are used in the treatment of certain types of immunologic and inflammatory diseases, including rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by selectively blocking mechanisms involved in the inflammatory and immune response. The purpose of this review is to help policy makers and clinicians make informed choices about the use of targeted immune modulators
|